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DNA methylation
Methylation of DNA is an epigenetic process which
modulates gene expression [1]. In the mammalian
genome, methylation is almost exclusively observed
at cytosines 50 to guanosines, i.e. in the CpG dinucleo-
tides. Many of these CpG islands are associated with
promoters [2,3]. Methylation of CpGs in the promoter
region has the potential to silence gene expression.
Mechanisms accounting for diminished or abrogated
gene expression following CpG methylation comprise
blocking of the binding of sequence-speciﬁc trans-
activating proteins or binding of proteins that inter-
fere with transcription [3,4]. Prominent examples of
gene silencing induced by CpG methylation comprise
X-chromosome inactivation in females, develop-
mental transcriptional regulation, genomic imprint-
ing, carcinogenesis and tissue-speciﬁc expression of
a gene [5–8].
Inhibition of DNA methyltransferase activity
A family of DNA methyltransferases (DNMTs) that
can catalyse cytosine methylation in different
sequence contexts has been identiﬁed. Inhibition of
DNMT enzymes by xenobiotics, antisense or small
interfering RNA resulted in lower steady-state methyl-
transferase activity, global or gene-speciﬁc methylation
and, most interestingly, in re-expression of silenced
genes [9,10]. Such a reactivation of genes by inhibitors
of DNMTs, including 5-aza-20-deoxycytidine (decita-
bine) and 5-azacytidine (azacitidine), has been shown
to be clinically useful for the treatment of tumours
attributable to repressed tumour suppressor genes or in
subjects with b-thalassaemia or sickle cell anaemia
by inducing hypomethylation of the g-globin chain
gene with effectively increased production of fetal
haemoglobin [10,11]. In studies of normal healthy
volunteers it is interesting to observe that the anti-
arrhythmic drug procainamide reverses CpG island
hypermethylation [7,12].
Examples of gene silencing by CpG methylation
in the ﬁeld of hypertension and nephrology
A fascinating observation is the distinct cell type-
speciﬁc expression of the native erythropoietin gene in
infrequent interstitial peritubular cells [8]. In this gene,
the promoter and 50-untranslated region comprise a
CpG island; methylation of the CpG island correlates
inversely with expression and, furthermore, methyla-
tion of this CpG island was shown to induce recruit-
ment of a methyl-CpG-binding protein to the promoter
and to block the association of nuclear proteins with
consecutive inhibition of expression [8,13].
Similarly to erythropoietin, the 11b-hydroxysteroid
dehydrogenase enzyme (11b-HSD2) exhibits a remark-
able cell-speciﬁc constitutive expression in mineralo-
corticoid target tissues such as epithelial cells from the
renal cortical collecting duct [14,15]. The main function
of the 11b-HSD2 enzyme is to protect the non-selective
mineralocorticoid receptor (MR) from activation by
11b-hydroxyglucocorticoids, such as cortisol in humans
or corticosterone in rodents. A reduced activity of 11b-
HSD2 leads an overactivation of the MR by cortisol,
with renal sodium retention, hypokalaemia and a salt-
sensitive increase in blood pressure. Recently, CpG
islands covering the promoter and exon 1 of 11b-HSD2
were found to be densely methylated in tissues and cell
lines with low expression but not those with high
expression of 11b-HSD2. Demethylation induced by
5-aza-20-deoxycytidine and procainamide enhanced the
transcription and activity of the 11b-HSD2 enzyme in
human cells in vitro and in rats in vivo. Methylation of
11b-HSD2 promoter–luciferase constructs decreased
transcriptional activity, and methylation of recognition
sequences of transcription factors known to be relevant
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for the expression of this enzyme diminished their
binding activity, indicating a role for the epigenetic
mechanism of DNA methylation for the expression
of this gene causally linked with hypertension [7].
A second gene possibly linked with blood pressure
regulation, endothelin-converting enzyme (ECE-1c),
recently has been shown to exhibit CpG islands in the
promoter [16]. In vitro methylation of these islands
reduced the activity of the ECE-1c promoter. These
observations made in cell cultures must be clariﬁed by
investigations in vivo, because methylation is a phenom-
enon that can occur in cell cultures as a result of the
inability of cell lines to express all of the functions
typical of the tissue from which they were derived.
Outlook
The prevalence of neoplastic diseases increases with age.
For many of the genes associated with carcinogenesis,
altered CpG methylation has been described to be
initiated during the course of ageing [17]. Similarly, the
prevalence of hypertension increases with age and it
is conceivable that the same fundamental molecular
mechanism, CpG methylation, accounts at least in
part for the age-dependent appearance of both disease
states.
The demonstration that the degree of CpG methyla-
tion in the promoter of the 11b-HSD2 gene determines
activity and tissue-speciﬁc expression of this enzyme
provides a kind of proof of principle for the relevance
of the methylation status of pivotal genes for blood
pressure control. It is difﬁcult to predict which of the
many candidate genes involved in the regulation of
blood pressure should be investigated with respect
to their relevance to DNA methylation, because most
housekeeping genes and 40% of genes with tissue-
speciﬁc expression contain CpG islands [2,3] and many
of these genes might change their methylation status as
a function of age or in the presence of disease states.
Furthermore, such changes might not be relevant due
to compensatory mechanisms abrogating the overall
effect on blood pressure.
Promising candidates worth investigating for CpG
methylation-dependent effects are those genes for
which exonic mutations have been shown to induce a
disease state, because these mutations unambiguously
indicate that a reduced or an enhanced expression of
the corresponding protein cannot be compensated by
other mechanisms. The vast majority of monogenic
diseases causing arterial hypertension are linked to
renal sodium handling in the cortical collecting duct
[18]. Thus, in a ﬁrst approach, these genes are reason-
able targets to be analysed with respect to regulation
by the epigenetic mechanism of CpG methylation, an
attractive contention in the light of the known age-
dependent sodium sensitivity in humans [19].
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